Gilead’s Seladelpar Hits Key Endpoint in Phase 3 PBC Trial

Event summary

  • Gilead’s Livdelzi (seladelpar) achieved statistically significant composite ALP normalization in the Phase 3 IDEAL trial for primary biliary cholangitis (PBC).
  • The study enrolled 96 adults with inadequately controlled PBC, showing Livdelzi’s efficacy in a broader patient population.
  • Safety profile remained consistent with prior studies, with no new concerns identified.
  • Full data to be presented at an upcoming medical congress, with regulatory discussions planned.

The big picture

Gilead’s positive Phase 3 data for Livdelzi reinforces its commitment to addressing unmet needs in liver disease, particularly in PBC. The focus on ALP normalization aligns with evolving treatment goals in the field, potentially expanding Livdelzi’s market reach. The results come at a time when biopharmaceutical companies are increasingly targeting rare liver diseases with precision therapies.

What we're watching

Regulatory Pathway
Whether Gilead can secure expanded approval for Livdelzi based on ALP normalization data.
Market Positioning
How these results position Livdelzi against existing PBC treatments in a competitive landscape.
Clinical Adoption
The pace at which physicians adopt Livdelzi for broader PBC patient populations.